Background/Purpose
Cancer
LUTZ, CANCER
Edited by: Yongjun Sui, National Cancer Institute (NIH), United StatesReviewed by: Stephen Lockhart, Pfizer, United Kingdom; Elizabeth De Gaspari, Adolfo Lutz Institute, BrazilOptimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination. This investigation aimed to explore the potential prime-boost COVID-19 vaccination strategies following autologous (auto-) HSCT.